Literature DB >> 15733523

The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis.

L Muratori1, P Muratori, A Granito, R Ferrari, L Veronesi, M Lenzi, F B Bianchi.   

Abstract

Anti-mitochondrial antibodies are the serological markers of primary biliary cirrhosis. We analysed the detailed anti-mitochondrial antibodies patterns to see whether the immunological specificities detected at the time of the diagnosis correlate with the histological, clinical and immunological expression of the disease. One hundred and thirty primary biliary cirrhosis patients were studied at the time of presentation/diagnosis. Anti-mitochondrial antibodies reactivity was dissected and evaluated by Western immunoblotting with bovine heart submitochondrial particles as antigenic source. Six different Western immunoblotting patterns have been identified with the following hierarchy: pattern A (anti-PDC-E2+anti-E3BP, 38.5%), pattern B (anti-PDC-E2+anti-E3BP+anti-OGDC-E2, 20.8%), pattern C (anti-PDC-E2+anti-E3BP+anti-BCOADC-E2+anti-OGDC-E2, 13.1%), pattern D (anti-PDC-E2+anti-E3BP+anti-BCOADC-E2, 6.9%), pattern E (anti-BCOADC-E, 6.1%) and pattern F (anti-mitochondrial antibodies negative primary biliary cirrhosis, 14.6%). The different patterns were neither associated with peculiar clinical, biochemical, histological and immunological features nor with the Mayo Risk Score. The anti-mitochondrial antibodies pattern at presentation is independent of the stage of the liver disease; therefore, the Western immunoblotting characterisation of anti-mitochondrial antibodies does not seem to be helpful in identifying the clinical, biochemical or histological expression of primary biliary cirrhosis at the time of the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15733523     DOI: 10.1016/j.dld.2004.09.019

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  4 in total

1.  High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?

Authors:  S Berardi; F Lodato; A Gramenzi; A D'Errico; M Lenzi; A Bontadini; M C Morelli; M R Tamè; F Piscaglia; M Biselli; C Sama; G Mazzella; A D Pinna; G Grazi; M Bernardi; P Andreone
Journal:  Gut       Date:  2006-06-23       Impact factor: 23.059

2.  Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?

Authors:  Antonio Maria Alfano; Alessandra Romito; Cristiana Marchese; Marco Battistini; Giliola Crotti; Arturo Ferrini; Cristina Mancinetti; Tilde Manetta; Giulio Mengozzi; Paola Merlach; Marco Migliardi; Maria Teresa Tambuzzo
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 3.  Popular and unpopular infectious agents linked to primary biliary cirrhosis.

Authors:  Andreas L Koutsoumpas; Stephen Kriese; Eirini I Rigopoulou
Journal:  Auto Immun Highlights       Date:  2012-10-23

4.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.